



Press release from Emotra AB (publ)

Göteborg, July 9th, 2021

Emotra signs agreement with King's College London, UK

An agreement for collaboration has been signed between Kings College in the UK and Emotra. According to the agreement, Emotra will provide EDOR technology and testing to the NESPRED study. The study is investigator-initiated, sponsored by the Medical Research Council (MRC) and independent from Emotra's planning of relapse-studies.

The NESPRED study at Kings College aims at studying neurocognitive signatures predicting risk of recurrent depression. The study will recruit recovered patients that have stopped taking their antidepressant medication and then monitored for depression recurrences. In this study, EDOR test will be used as one of several different technologies and measurements to build a prediction model for recurrent depression.

This collaboration comes from a first contact with the group during the launch efforts in London in early 2019, when Emotra was active in its first launch for EDOR test. The study is investigator-initiated by Dr. Roland Zahn at Institute of Psychiatry, Psychology and Neuroscience, Centre for Affective Disorders and is independent from the research planned on depression relapse by Emotra. For the NESPRED study, Emotra provides technology, testing, support, and services and will obtain anonymised data through a data-sharing agreement. The study is expected to begin its recruitment of patients in August 2021 and continue until January 2026 and the equipment and testing will be provided free of charge.

"This is a unique opportunity for Emotra to take part in high quality clinical research to acquire more data and information on hyporeactivity in a clinical environment from a unique patient population. It is an excellent example of collaborations with a shared goal that hold a lot of value for both Emotra and King's College London. The Centre for Affective Disorders at the Department of Psychological Medicine is one of the leading institutions in the mood disorder area. We have been met with professionalism and have come to appreciate the breadth of knowledge in the mood disorders area present at the centre". Says Daniel Poté, CEO of Emotra.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.